TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
17.56
-0.29 (-1.62%)
At close: 4:01PM EDT

17.60 +0.04 (0.23%)
Pre-Market: 4:42AM EDT

Stock chart is not supported by your current browser
Previous Close17.85
Open17.81
Bid17.56 x 500
Ask17.60 x 2100
Day's Range17.49 - 18.39
52 Week Range10.85 - 33.82
Volume11,732,968
Avg. Volume12,653,820
Market Cap17.856B
Beta1.02
PE Ratio (TTM)N/A
EPS (TTM)-16.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.29
Trade prices are not sourced from all markets
  • MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble
    Yahoo Finance Video5 days ago

    MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • Reuters16 hours ago

    Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc (AMGN.O), Eli Lilly and Co (LLY.N) and other makers of new migraine medicines to try and fix it. Express Scripts (ESRX.O) told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reuters21 hours ago

    Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reuters22 hours ago

    FOCUS-Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Mylan NV Still Undervalued Despite Unveiling of New Products
    InvestorPlace2 days ago

    Mylan NV Still Undervalued Despite Unveiling of New Products

    Mylan NV (NASDAQ:MYL), while still trending upward on the stock market, is on pause and without direction at the moment. Markets do not yet recognize the growth potential in MYL stock. It produces the global supply of EpiPens for Mylan, but has manufacturing problems at its Missouri plant.

  • Analysts’ Recommendations for Eli Lilly & Co. on April 20
    Market Realist2 days ago

    Analysts’ Recommendations for Eli Lilly & Co. on April 20

    Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.

  • Business Wire2 days ago

    Teva to Report First Quarter 2018 Financial Results on May 3, 2018

    Teva Pharmaceutical Industries Ltd. announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET.

  • Teva, Procter & Gamble to dissolve OTC partnership.
    American City Business Journals6 days ago

    Teva, Procter & Gamble to dissolve OTC partnership.

    The joint venture called PGY Healthcare sells OTC product in more than 50 countries outside North America. The company will terminate operations on July 1.

  • Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
    Market Realist6 days ago

    Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

    Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.

  • P&G sales, earnings per share climb
    American City Business Journals6 days ago

    P&G sales, earnings per share climb

    “We delivered modest top- and bottom-line growth in a challenging macro environment in the third quarter,” CEO David Taylor said.

  • Business Wire6 days ago

    Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership

    Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using market-leading brands such as Vick’s and ratiopharm.

  • Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
    Market Realist6 days ago

    Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.

  • Jazz Pharmaceuticals: How It’s Positioned before 1Q18
    Market Realist7 days ago

    Jazz Pharmaceuticals: How It’s Positioned before 1Q18

    In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.